Compare Eli Lilly And Co (LLY) vs Procter & Gamble Co (PG) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Procter & Gamble (PG) trades at $149.96, down 1.0% on the day, with a bullish technical signal supported by moving averages. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.41. Revenue reached $84.28 billion in 2025, with a net income margin of 19.16%. Recent news highlights PG's dividend reliability and a new WNBA partnership, while analyst consensus leans bullish with a $161.71 price target.

PG offers stable growth and dividend income, supported by strong cash flow and brand strength. Risks include premium valuation concerns and soft demand outlook. Upside potential exists if earnings continue to exceed expectations, but investors should monitor margin pressures and competitive dynamics in consumer goods.